1,200 mg/m2/d for 2 days, leucovorin 400 mg/m2, oxaliplatin 85 mg/m2) × 12 cycles
Treatment received (specify dates, location, and providers):
Received FOLFOX from 11/10/04 to 04/13/05 at Northside Cancer Institute under the supervision of Dr. Jane Marks.
Unusual or unexpected toxicities during treatment:
Expected short- and long-term effects of treatment:
Sixth cycle held 1 week for thrombocytopenia, requiring a dose reduction in oxaliplatin to 65 mg/m2. Experienced cold-induced paresthesias in the hands and feet, but no residual neuropathy.
Late toxicity monitoring needed:
Surveillance needed for potential recurrence of cancer:
Clinical assessments and bloodwork including CEA every 3 months for 2 years, every 4 months for 1 year, then every 6 months for 2 years. After 5 years, either follow up on an as-needed basis or every 1–2 years, depending on patient choice.
Surveillance needed for second malignancies:
Colonoscopy 1 year after hemicolectomy. Subsequent schedule to depend on the findings. If not polyps or other disease, repeat every 3 to 5 years.
Physicians responsible for monitoring of toxicity, recurrence, second malignancies:
Dr. Jane Marks
Identified psychosocial issues or concerns:
Normal anxiety. Has contact with social worker, David Jones, as needed.
Recommended preventive behaviors, interventions, or genetic testing:
None specific for this cancer. Routine medical care recommended. Patient counseled regarding diet/nutrition. Patient given NCI booklet, Life After Cancer Treatment, and the NCCS “Cancer Survival Toolbox: An Audio Resource Program” that address medical and psychosocial issues, including those related to health insurance and employment.
NOTE: All individual and hospital names are fictitious.
SOURCE: Craig Earle, committee member, 2005.